PLACEMENT AGENCY AGREEMENT September 27, 2016Placement Agency Agreement • May 15th, 2017 • Citius Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
FORM OF COMMON STOCK PURCHASE WARRANT CITIUS PHARMACEUTICALS, INC.Security Agreement • May 15th, 2017 • Citius Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Citius Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to ______ shares (the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
FORM OF UNIT PURCHASE AGREEMENTUnit Purchase Agreement • May 15th, 2017 • Citius Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
UNIT PURCHASE AGREEMENT (this “Agreement”) made as of the date set forth on the signature page hereof between Citius Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and the subscriber(s) identified on Exhibit A annexed hereto (the “Subscriber”).
AMENDMENT TO PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • May 15th, 2017 • Citius Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Amendment to Placement Agency Agreement (the “Amendment”) is made on November 23, 2016, by and between Citius Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and Garden State Securities, Inc. (“GSS”). All terms not defined herein shall have the meaning designated in the Agreement (as defined below).
CONVERSION AGREEMENTConversion Agreement • May 15th, 2017 • Citius Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
This Conversion Agreement (this “Agreement”) is effective as of May 10, 2017 (the “Effective Date”) by and between Citius Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and Leonard Mazur (the “Lender”).
SECOND AMENDMENT TO PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • May 15th, 2017 • Citius Pharmaceuticals, Inc. • Pharmaceutical preparations
This Second Amendment to Patent and Technology License Agreement (the “Amendment”) is made as of the 20th day of March 2017 to the Patent and Technology License Agreement effective as of May 14, 2014, as amended (the “Agreement”), by and between Novel Anti-Infective Technologies, LLC (the “Licensor”), and Leonard-Meron Biosciences, Inc. (“Licensee”). Terms used herein that are not otherwise defined herein shall have the meanings given them in the Agreement.
